Ask AI

Lung Cancers

Share

Program Content

Events

Activities

  • TROPION-Lung02
    TROPION-Lung02: Phase I Study of First-line Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • HERTHENA Lung02
    HERTHENA-Lung02: Phase III Trial of Patritumab Deruxtecan (HER3-DXd) vs Chemotherapy in EGFRm Advanced NSCLC After a 3rd-Generation EGFR TKI
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • SACHI
    SACHI: Phase III Trial of Savolitinib + Osimertinib vs Chemotherapy in EGFR-Mutant, MET-Amplified Advanced NSCLC After an EGFR TKI
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • SAVANNAH Randomized Subset
    SAVANNAH Subset: Savolitinib ± Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • ALNEO
    ALNEO: Phase II Trial of Perioperative Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • Beamion LUNG 1 PRO
    Beamion LUNG-1: Patient-Reported Outcomes With Zongertinib for Previously Treated Advanced HER2-Mutant NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • IMforte
    IMforte: Phase III Trial of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • NeoADAURA
    NeoADAURA: Neoadjuvant Osimertinib ± CT vs CT Alone in Resectable EGFRm NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2025

    Expires: December 05, 2025

  • ACHILES
    ACHILES: Randomized Phase II Study of Atezolizumab vs Observation After Chemoradiotherapy for Limited-Stage SCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2025

    Expires: December 05, 2025

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar